Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.95
0.170.86%
At close: -
$19.78
-0.17-0.85%
After Hours: 7:56 PM EDT
Comments
Loading...
Summit Therapeutics Analyst Ratings and Price Targets | NASDAQ:SMMT | Benzinga
Summit Therapeutics Inc has a consensus price target of $34.5 based on the ratings of 13 analysts. The high is $44 issued by Jefferies on April 25, 2025. The low is $12 issued by Leerink Partners on June 11, 2025. The 3 most-recent analyst ratings were released by Leerink Partners, JMP Securities, and Goldman Sachs on June 11, 2025, June 2, 2025, and May 2, 2025, respectively. With an average price target of $31 between Leerink Partners, JMP Securities, and Goldman Sachs, there's an implied 56.72% upside for Summit Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
JMP Securities
Goldman Sachs
Jefferies
Citigroup
1calculated from analyst ratings
Analyst Ratings for Summit Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/11/2025 | Buy Now | -39.33% | Leerink Partners | Daina Graybosch43% | → $12 | Initiates | → Underperform | Get Alert |
| 06/02/2025 | Buy Now | 102.22% | JMP Securities | Reni Benjamin49% | $40 → $40 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/02/2025 | Buy Now | 107.28% | Goldman Sachs | Salveen Richter52% | $37 → $41 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 102.22% | JMP Securities | Reni Benjamin49% | $40 → $40 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/25/2025 | Buy Now | 122.45% | Jefferies | Kelly Shi43% | $31 → $44 | Maintains | Buy | Get Alert |
| 04/23/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt34% | — | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2025 | Buy Now | 76.95% | Citigroup | Yigal Nochomovitz54% | $23 → $35 | Upgrade | Neutral → Buy | Get Alert |
| 03/21/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt34% | — | Initiates | → Overweight | Get Alert |
| 03/12/2025 | Buy Now | 51.67% | Evercore ISI Group | Cory Kasimov67% | → $30 | Initiates | → Outperform | Get Alert |
| 02/28/2025 | Buy Now | 112.34% | Goldman Sachs | Salveen Richter52% | → $42 | Initiates | → Buy | Get Alert |
| 02/25/2025 | Buy Now | 61.78% | Citizens Capital Markets | Reni Benjamin49% | $32 → $32 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/25/2025 | Buy Now | 122.45% | HC Wainwright & Co. | Mitchell Kapoor46% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 01/21/2025 | Buy Now | 122.45% | HC Wainwright & Co. | Mitchell Kapoor46% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 76.95% | Truist Securities | Asthika Goonewardene43% | → $35 | Initiates | → Buy | Get Alert |
| 12/11/2024 | Buy Now | 51.67% | Wells Fargo | Mohit Bansal68% | → $30 | Initiates | → Overweight | Get Alert |
| 12/06/2024 | Buy Now | 56.72% | Jefferies | Brent Thill77% | → $31 | Initiates | → Buy | Get Alert |
| 11/18/2024 | Buy Now | 122.45% | HC Wainwright & Co. | Mitchell Kapoor46% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 11/04/2024 | Buy Now | 61.78% | JMP Securities | Reni Benjamin49% | → $32 | Initiates | → Market Outperform | Get Alert |
| 10/31/2024 | Buy Now | 122.45% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $44 | Maintains | Buy | Get Alert |
| 10/04/2024 | Buy Now | 127.5% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 16.28% | Citigroup | Yigal Nochomovitz54% | $19 → $23 | Downgrade | Buy → Neutral | Get Alert |
| 09/25/2024 | Buy Now | 102.22% | Stifel | Bradley Canino41% | $25 → $40 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 127.5% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 127.5% | HC Wainwright & Co. | Mitchell Kapoor46% | $30 → $45 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | -3.94% | Citigroup | Yigal Nochomovitz54% | $13 → $19 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 26.39% | Stifel | Bradley Canino41% | $14 → $25 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 51.67% | HC Wainwright & Co. | Mitchell Kapoor46% | $16 → $30 | Maintains | Buy | Get Alert |
| 09/03/2024 | Buy Now | -19.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2024 | Buy Now | -19.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | -19.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | -19.11% | HC Wainwright & Co. | Mitchell Kapoor46% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | -19.11% | HC Wainwright & Co. | Mitchell Kapoor46% | → $16 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | -29.22% | Stifel | Bradley Canino41% | $8 → $14 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | -34.28% | Citigroup | Yigal Nochomovitz54% | $7 → $13 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | -64.61% | Citigroup | Yigal Nochomovitz54% | → $7 | Initiates | → Buy | Get Alert |
| 03/26/2024 | Buy Now | -59.56% | Stifel | Bradley Canino41% | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Summit Therapeutics (SMMT) stock?
The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Leerink Partners on June 11, 2025. The analyst firm set a price target for $12.00 expecting SMMT to fall to within 12 months (a possible -39.33% downside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Summit Therapeutics (SMMT)?
The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by Leerink Partners, and Summit Therapeutics initiated their underperform rating.
When was the last upgrade for Summit Therapeutics (SMMT)?
The last upgrade for Summit Therapeutics Inc happened on March 26, 2025 when Citigroup raised their price target to $35. Citigroup previously had a neutral for Summit Therapeutics Inc.
When was the last downgrade for Summit Therapeutics (SMMT)?
The last downgrade for Summit Therapeutics Inc happened on September 27, 2024 when Citigroup changed their price target from $19 to $23 for Summit Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Summit Therapeutics (SMMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on June 11, 2025 so you should expect the next rating to be made available sometime around June 11, 2026.
Is the Analyst Rating Summit Therapeutics (SMMT) correct?
While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a initiated with a price target of $0.00 to $12.00. The current price Summit Therapeutics (SMMT) is trading at is $19.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
